SBC003: Rescuing Vision, Dominating Markets

– The First-in-Class Oral Pill Leading a $60B+ Neurodegeneration Revolution

SunRegen

SunRegen Healthcare AG

European Commission
Horizon 2020
European Union funding for Research & Innovation
SEAL OF EXCELLENCE

Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra
Swiss Confederation
Innosuisse – Swiss Innovation Agency

David Guan, CEO
david.guan@sunregen.ch

Neurodegenerative Eye Diseases – Significant Unmet Medical Needs

Normal Eye

80% of perception of external information comes from the eye



- ***95.5 million*** photoreceptors | ***1 million*** retinal ganglion cells



Neurodegenerative Eye Diseases

No Effective Drugs Available



- ***Retinitis Pigmentosa (RP)***
  Degeneration of rods & cones
- ***Dry AMD (DAMD)***
  Affects central region of the retina
- ***Optical Atrophy (AO)***
  Degeneration of retinal nerve fibers

Huge Blue Ocean Market: RP, DAMD, GOA, and POA， Market Scale: ~$1000B

Global Market & Patients in USA, Japan, EU and China



* Source: www.Globaldata.com

- Retinitis Pigmentosa (RP)
- Dry-AMD (DAMD)
- Glaucoma Optic Atrophy (GOA)
- Primary Optic Atrophy (POA)

1. The incidence of glaucoma is 1% in the overall population and 2% after the age of 45. 10% are visually impaired of the 70 million patients worldwide.
2. Age-related Macular Degeneration (AMD), 85%-90% of which is dry-AMD.
3. Existing wet-AMD drugs have an annual cost of $14,000-$23,500 per patient.

Unique Selling Points of SBC003 for Neurodegenerative Conditions

SBC003 Targets the Root Causes of Neurodegenerative Conditions



Selling Points

1. Neurorescuing

Restores viability of dying neurons

2. Neuroprotection



Protects the healthy neurons

3. Neurite Outgrowth

Promotes neurite outgrowth

4. Protect Against Broad Etiologies

Therapeutic potential in multiple neurodegenerative conditions

5. Enter the Brain & Retina



Pass BBB & Retina

Proven Neuroprotective & Neurorescuing Effects in Models for Retinitis Pigmentosa and Dry-AMD

Neuroprotective effects in an NMU-induced mice with photoreceptor loss (ARVO 2020)





Neurorescuing effects in *rd10* mice model with fast photoreceptor loss





SBC003 Rescued RNFL Thickness and IZ in Monkeys with Optic/Retinal Degeneration

1. Direct Evidence of RNFL Thickness of SBC003 in Monkeys with Optic Atrophy









2. OCT Direct Evidence of Reformed Interdigitation Zone (IZ) from SBC003 Treated Monkeys



MOA1: SBC003 Exerts Neuro-rescuing & Neuroprotective Effects via Anti-Apoptotic Mechanism

SBC003 **exerts its pharmacological effects by upregulating neuroglobin *(NGB)* which is an endogenous anti-neuronal apoptosis therapeutic target**



SBC003 Induces Almost **Six-fold** Increased NGB Expression



MOA2: SBC003 Exerts Neuro-rescuing & Neuroprotective Effects Against Misfolded Neurotoxins

SBC003 exerts its effects by decreasing the misfolded protein toxins such as α-Synuclein, tau, and amyloid beta plaques



SBC003 Could Be An Ideal Therapeutic Candidate for RP, DAMD, OA, AD, and PD.

SBC003

SBC003 will not only bring hope for
retinal neurodegenerative diseases





- ***RP***
  Retinitis Pigmentosa
- ***OA***
  Optic Atrophy
- ***DAMD***
  Dry Age-Related Macular Degeneration

But also bring hope for
CNS neurodegenerative diseases



- ***Stroke***
  Stroke Disease
- ***AD***
  Alzheimer's Disease
- ***PD***
  Parkinson's Disease
- ***Others***
  … …

SBC003 Has Favorable Safety and Tolerability, and Simple Non-invasive Administration Route

- ✓ SBC003 origin from herb medicine which has been used safely for over thousand years
- ✓ Based on its chemical structure, SBC003 contains no structural moieties of toxic concern
- ✓ There is no toxic or side effect in many in-vitro and in-vivo studies, up to 1000 mg/kg.
- ✓ SBC003 has been tested in large animals including monkeys, demonstrating favorable safety and tolerability.

Favorable Oral Dosage



SBC003 *in vivo* safety and tolerability reaffirms suitability to be taken forward into IND enabling and phase 1 clinical trial

Multiple Nobel Prize Laureates and Scientific Experts Have Endorsed SBC003 Project

Prof. Eric R. Kandel

2000 Nobel Prize Laureate

I buy in the data. Fantastic!!
I endorse your project !

May 2017

Prof. Thomas C. Südhof

2013 Nobel Prize Laureate

The effects on cultured neurons are truly impressive. Clearly this is a very promising compound.

Nov 20, 2019

Dr. Thomas Hohman

Ophth Drug Development Expert

Despite these extensive efforts we were unable to identify a compound with the therapeutic potential of SunRegen's SBC003

Dec 29, 2019

First-in-Class Drug, Breakthrough Therapy

Early discovery stage is risky and very expensive (up to $1 billion by big pharma), but SunRegen has passed it.
Now SunRegen is advancing SBC003 to clinical with smart quick-win strategy

Quick-win strategy

Program	Indication	In vitro	In vivo	IND	Ph I	Ph II	Ph III
SBC003-01	Retinitis Pigmentosa (RP)						
SBC003-02	Dry AMD						
SBC003-03	Optic Atrophy(OA)						
SBC201	AD, PD, etc.						

Setup Strong IP Moat. PCT1 was granted by 11 Patent Offices.

SBC003 Has A Blockbuster Potential with RP Indication

Breakthrough Therapy for Retinitis Pigmentosa (RP)

- ✓ **Good Efficacy**: SBC003 can reverse the apoptosis of photoreceptor cells
- ✓ **Wide Coverage**: it is not limited to a certain gene mutation type; its coverage is much higher than that of gene therapy.
- ✓ **High Acceptability**: oral dosage, which is easily accepted by patients, much better than intravitreal injection.
- ✓ **High Safety**: It has an extremely low incidence of side effects.
- ✓ **Low Cost**: The production cost is very low, which reduces the cost for patients.

RP Projected Peak Annual Sale: $5B



More than Blockbuster Potential of SBC003

SBC003 Projected Peak Sales ($B)



2023 Pharma Sales vs SBC003 Projected Peak Sales ($B)



Management estimate based on data from Globaldata.com

- 4th Target Market: **…$B**
- 3rd Target Market, **OA: > $5.2B**
- 2nd Target Market, **Dry AMD: $55B**
- 1st Target Market, **RP: $5.3B**

Low competition in huge blue ocean markets:

1st → Target market: ***RP***

2nd → Target market: ***Dry AMD***

3rd → Target market: ***OA***

4th → Target market: ***AD, PD, etc.***

A Passionate Management Team With Extensive Experience With World-class Advisors

Strong track records of professional success and achievement



David Guan

MSc, Founder, CEO

- Master of E.E.
- 10 years in management positions at multinational companies
- 10+ years as entrepreneur
- Solid business operation, management and cross-culture team management.

Dr. Yuhong Dong

MD, PhD, Founder, CMO, CSO

- MD, PhD, Postdoc in Beijing University & CAMS
- Senior Medical Scientific Expert in Novartis Basel
- 4 Novartis Awards, 30+ publications
- Talented in drug R&D to resolve unmet medical needs

Dr. Hans-Jürgen Pfannkuche

PhD, Head of R&D

- Ph.D., Postdoc
- Pharmacovigilance Professional and Preclinical & Clinical Pharmacologist with 35 years of Team & Project Lead Expertise and thorough Experience in Drug Safety, Drug Discovery & Development, and Registration Affairs

Scientific Advisors

Dr. Matthias Staufenbiel

Neurodegenerative Diseases Expert

24+ years in leading positions at Novartis and Sandoz Preclinical Neuroscience Research focusing on neurodegenerative diseases

Dr. Philip Bentley

Preclinical Development Expert

40+ years of experience in the fields of drug metabolism and toxicology including V.P. & Global Head Preclinical Safety at Novartis

Dr. Thomas Hohman

Ophth Drug Development Expert

An established industry leader who oversaw the development of multiple ophthalmology therapies in Alcon, Allergan and Novartis for over 30 years

Dr. Kin-Sang (Anson) CHO

Retinal Degeneration Expert

Principal Scientist at the Schepens Eye Research Institute and a Principal Associate at the Department of Ophthalmology, Harvard Medical School

Awards and Grants

Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Innosuisse – Swiss Innovation Agency

Innosuisse supported grants over *CHF 1 million* since 2017

BIO-EUROPE®

NOVEMBER 5-7, 2018
COPENHAGEN, DENMARK

The *Winner* of BioEurope 2018 Startup Slam Copenhagen

Johnson & Johnson

INNOVATION | JLABS

Selected by JLABS@BE JLABS@Shanghai

BASELAUNCH
accelerating healthcare ventures

Baselaunch portfolio

MAGINE IF Innovation Forum Swiss Final

European Commission

SME Instrument

European Commission SME Instrument Grant (EU Horizon 2020 program)

Business Plan and Financing

R&D Plan

IND-Enabling	Phase 1	Phase 2a	NDA for RP
CMC, DMPK, GLP Tox	SAD+MAD in HV	POC for RP in 40 patients	Launch drug for RP, post-market clinical trials
			Phase 2,3 for Dry AMD, OA

Key Milestones

2024 — 2025 — 2026 — 2027 — 2028 — 2029

IND — Phase 1 — NDA

Financing

1. Pre-A $1.5M — Post-Value: $25M
2. Pre-IPO $6-10M — TBD
3. IPO $20M — Estimate: ~$300M
4. Estimate: ~$3B
5. Estimate: >$30B

High Potential Molecule with Neurorescuing Effects on Retinal Neurodegeneration

Breakthrough Innovation → **Huge Social Benefits** → **Blockbuster Potential**

Innovative Discovery

- Phenotypic observed effect
- MedChem to explore backup candidates
- 1st PCT approved from US, CN, JP, AU, SG, CL, NZ, WT

Lead Compound

- Neuro-rescuing
- Neuroprotective
- Orally bioavailable
- Significant efficacy in mice and monkey models

Experienced Team

- Decades of Pharma experience
- World-class scientific advisors
- Key functional experts to ensure full capability

Clear Path

- RP indication for quick-win
- Followed by big diseases
- Highly unmet ophthalmic conditions
- Advance to human trials ASAP

Revive Nerves, Reclaim Lives

SBC003

Welcome To Join the Game-Changing Program!

SunRegen Healthcare AG

Business Parc Reinach
Christoph Merian-Ring 11,
4153 Reinach, BL, Switzerland
Email: info@sunregen.ch
Website: https://www.sunregen.ch